The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
- PMID: 3490988
- DOI: 10.1016/0014-2999(86)90444-9
The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice
Abstract
The effects of different dosing paradigms for the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were investigated in C57-black and CF-W albino mice. Several groups of mice received a total dose of 80 mg/kg of MPTP administered at different doses per injection and/or at different time intervals. In C57-black mice, the effects of MPTP administration on the neostriatal content of dopamine ranged from a 91% depletion (4 injections of 20 mg/kg per injection at 1 h intervals) to a non-significant effect (4 injections of 10 mg/kg per injection at 2 h intervals on each of 2 successive days). There was also considerable influence of the MPTP dose per injection and the dosing interval in CF-W mice, although the extent of neostriatal dopamine depletion in CF-W mice was not as great as that observed in C57-black mice. In addition, MPTP produced variable effects on neostriatal dopamine levels in different strains of mice as well as in Swiss-Webster mice obtained from different sources. Some of the strains were affected to a great extent while others were only marginally affected.
Similar articles
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity.Eur J Pharmacol. 1986 Jan 29;120(3):375-7. doi: 10.1016/0014-2999(86)90482-6. Eur J Pharmacol. 1986. PMID: 2868908
-
Differential neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in Swiss-Webster mice from different sources.Eur J Pharmacol. 1985 Oct 29;117(1):131-3. doi: 10.1016/0014-2999(85)90482-0. Eur J Pharmacol. 1985. PMID: 3878793
-
Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the mouse: relationships between monoamine oxidase, MPTP metabolism and neurotoxicity.Life Sci. 1985 Jan 21;36(3):231-6. doi: 10.1016/0024-3205(85)90064-5. Life Sci. 1985. PMID: 3917525
-
Synthesis and toxicity toward nigrostriatal dopamine neurons of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues.J Med Chem. 1986 Mar;29(3):424-7. doi: 10.1021/jm00153a019. J Med Chem. 1986. PMID: 3485197
-
Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.Mol Chem Neuropathol. 1989 Jun;10(3):171-83. doi: 10.1007/BF03159727. Mol Chem Neuropathol. 1989. PMID: 2669769 Review. No abstract available.
Cited by
-
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.BMC Biol. 2004 Oct 11;2:22. doi: 10.1186/1741-7007-2-22. BMC Biol. 2004. PMID: 15473914 Free PMC article.
-
Postnatal iron overload destroys NA-DA functional interactions.J Neural Transm (Vienna). 2007 Feb;114(2):195-203. doi: 10.1007/s00702-006-0522-6. Epub 2006 Aug 24. J Neural Transm (Vienna). 2007. PMID: 16932993
-
The PPARgamma agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B.Br J Pharmacol. 2008 May;154(1):226-33. doi: 10.1038/bjp.2008.78. Epub 2008 Mar 10. Br J Pharmacol. 2008. PMID: 18332857 Free PMC article.
-
Neurobehavioural deficits following postnatal iron overload: I spontaneous motor activity.Neurotox Res. 2003;5(1-2):53-76. doi: 10.1007/BF03033373. Neurotox Res. 2003. PMID: 14628856 No abstract available.
-
Levodopa-induced dyskinesia: a historical review of Parkinson's disease, dopamine, and modern advancements in research and treatment.J Neurol. 2022 Jun;269(6):2892-2909. doi: 10.1007/s00415-022-10963-w. Epub 2022 Jan 17. J Neurol. 2022. PMID: 35039902 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources